Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.

@article{Meuillet2010MolecularPA,
  title={Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.},
  author={Emmanuelle J. Meuillet and Song Zuohe and Robert Lemos and Nathan T. Ihle and John Kingston and Ryan D Watkins and Sylvestor A Moses and Shuxing Zhang and Lei Du-Cuny and Roy S. Herbst and J{\"o}rg J. Jacoby and Li Li Zhou and Ali Md Ahad and Eugene A. Mash and D. Lynn Kirkpatrick and Garth Powis},
  journal={Molecular cancer therapeutics},
  year={2010},
  volume={9 3},
  pages={706-17}
}
Phosphatidylinositol 3-kinase/phosphatidylinositide-dependent protein kinase 1 (PDPK1)/Akt signaling plays a critical role in activating proliferation and survival pathways within cancer cells. We report the molecular pharmacology and antitumor activity of PHT-427, a compound designed to bind to the pleckstrin homology (PH) binding domain of signaling molecules important in cancer. Although originally designed to bind the PH domain of Akt, we now report that PHT-427 also binds to the PH domain… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Recent progress in the discovery of Akt inhibitors as anticancer agents

  • Q. Li
  • Expert Opin Ther Patents
  • 2007
Highly Influential
5 Excerpts

In vitro and in vivo antitumor activities of MK-2206, a new allosteric AKT inhibitor

  • W Lu, D Defeo-Jones, L Davis
  • Proc Am Assoc Cancer Res Annu Meet 2009;2009:3714
  • 2009
Highly Influential
3 Excerpts

PDK1-SGK3 signaling in the absence of AKT activation in PIK3CA-mutant cancers

  • KM Vasudevan, DA Barbie, MA Davies
  • Cancer Cell 2009;16:21–32
  • 2009
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…